Maniinc revises full-year earnings forecast due to product recall

Maniinc today announced a revision to its full-year earnings forecasts for the fiscal year ending August 31, 2025, attributing the change primarily to the voluntary recall of its "MANI DIA-BURS" dental products in China. The company expects the recall to decrease sales by JPY1,330 million for the nine months ending May 31, 2025, and by JPY1,520 million for the full fiscal year, with a corresponding impact on operating income of JPY1,040 million and JPY1,200 million respectively. While the recall is expected to be completed by August 2025, the immediate effect necessitates the adjustment to financial projections. The revised forecast also incorporates assumptions related to ongoing U.S. tariff policies. As a result, the company now anticipates net sales of JPY29,600 million, operating income of JPY7,900 million, and profit attributable to owners of the parent of JPY5,450 million. This represents a decrease from previous forecasts of JPY30,200 million, JPY8,900 million, and JPY6,350 million respectively. The company is working to resume sales of the "MANI DIA-BURS" lineup in China by March 2026.